Nivolumab treatment in melanoma patients has manageable safety profile

28 mayo 2015

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Medical researchers have presented data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients.